Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo

NCT ID: NCT04221230

Last Updated: 2025-05-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 204 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-03
• Study Completion Date: 2022-06-23

Brief Summary

A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.

Conditions

Major Depressive Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

NMRA-335140 (BTRX-335140)

NMRA-335140 will be administered.

Group Type: EXPERIMENTAL

NMRA-335140

Intervention Type: DRUG

Active Drug

Placebo

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

NMRA-335140

Active Drug

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Other Intervention Names

BTRX-335140

Eligibility Criteria

Inclusion Criteria

Participants are eligible to be included in the study only if they meet all the following criteria:

1. Are adult men or women between 18 to 65 years of age (inclusive) at informed consent

2. Have a primary DSM-5 diagnosis of MDD, with prominent symptoms of anhedonia confirmed by Structured Clinical Interview for DSM-5 Disorders, Clinical Trials Version (SCID-5-CT)

1. The current episode must have started at least 3 weeks prior to screening visit but no more than 12 months before the screening visit.

2. Have not failed 2 or more courses of antidepressant treatment in the current episode

3. Have no more than a 3-point change in HAMD 17 between screening and baseline

4. Have sufficient history or an independent report to confirm that symptoms are causing functional impairment or clinically significant distress

3. Meet the blinded rule list based on clinical scale criteria

4. Have body mass index (BMI) between 18-40 kg/m2 (inclusive)

5. Are medically stable (in the opinion of the investigator and Sponsor/Sponsors delegate) based on medical history, vital signs, clinical laboratory tests, and 12-lead electrocardiogram (ECG) performed at screening and baseline

6. Agree to the following birth control:

1. Nonvasectomized men must agree to use a condom with spermicide, if sexually active during the study, until 90 days after the last dose of study drug administration. No restrictions are required for a vasectomized man, provided his vasectomy was performed 4 months or more prior to the first dose of study drug. A man who has been vasectomized less than 4 months prior to the first dose of study drug must follow the same restrictions as a nonvasectomized man. Additionally, men must refrain from sperm donation during study treatment and for at least 90 days following the last dose of study drug.

2. Women of child-bearing potential (women not surgically sterilized and between menarche and 2 years postmenopausal) must have a negative serum pregnancy test at screening and a negative urine pregnancy test at enrollment and agree to use reliable birth control (eg, oral contraceptives or Norplant®; a reliable double barrier method of birth control (diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam); intrauterine devices; partner with vasectomy; or abstinence) during the study and for 10 days following the last dose of the study drug (BTRX-335140 or placebo). Women will be considered surgically sterile, if they have had tubal ligation, bilateral salpingo oophorectomy, or a hysterectomy.

Note: Abstinence will be allowed if, in the investigator's judgement, it is determined that the participant is reliable, that abstinence is the preferred and usual lifestyle of the participant, and that abstinence will be continued for the duration of the study including the 10 days (women) or 90-day period (men) following last dose of study drug as noted above.

3. Or engaged exclusively in a non-heterosexual relationship

7. Willing and able to give written informed consent to participate

8. Able to understand and comply with instructions in English

9. Are judged by the investigator to be reliable and agree to keep all appointments for clinic visits, tests, and procedures, including venipuncture, and examinations required by the protocol

Exclusion Criteria

Participants will be excluded from the study if they meet any of the following criteria:

1. Have a history of any of the following DSM-5 disorders within the specified timeframe:

1. Currently or in the past year: diagnosis of personality disorder, attention deficit disorder/attention deficit hyperactivity disorder, anorexia nervosa, or bulimia nervosa. Participants with comorbid generalized anxiety disorder, social anxiety disorder, or panic disorder for whom MDD is considered the primary diagnosis are not excluded.

2. Lifetime: diagnosis of bipolar 1 or 2, schizophrenia, obsessive compulsive disorder, or post-traumatic stress disorder

2. Have a history of substance or alcohol use disorder (AUD), per DSM-5 criteria, within the past year

3. Are actively suicidal (eg, any suicide attempts within the past 12 months) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) (score of "YES" on suicidal ideations item 4 or 5 within 3 months prior to Visit 1 (Screening) and/or based on clinical evaluation by the investigator; or are homicidal, in the opinion of the investigator

4. Have a history or signs of Cushing's disease, Addison's Disease, primary amenorrhea or other evidence of significant disorders of the hypothalamus-pituitary-adrenal axis

5. Have any other clinically significant medical or psychiatric condition or circumstance prior to randomization that, in the opinion of the investigator, or Sponsor, could affect participant safety, preclude evaluation of response, interfere with the ability to comply with study procedures, or prohibit completion of the study, such as acute stress disorder, adjustment disorder, impulse control disorder, uncontrolled diabetes mellitus, renal or hepatic impairment, coronary artery disease, evidence of significant active cardiac, respiratory, or hematologic disease, cancer with <5 year remission (basal cell carcinoma is not excluded), chronic pain, fibromyalgia, gastric bypass, lap band placement, or any other significant gastrointestinal condition

6. Have had prior seizures (other than remote history of childhood febrile seizure) or other condition that would place the participant at increased risk of seizures or is taking anticonvulsants for seizure control

7. Have a history of serious head injury (eg, skull fracture, cerebral contusion, or trauma resulting in prolonged unconsciousness), intracranial neoplasm, or hemorrhage

8. Have ever had electroconvulsive treatment, vagal nerve stimulation, or treatment with ketamine or esketamine for MDD

9. Have initiated transcranial magnetic stimulation, psychotherapy (such as Cognitive Behavioral Therapy) or have had a change in psychotherapy, or other non-drug therapies (such as acupuncture or hypnosis) within 4 weeks prior to Visit 1 (Screening) or at any time during the acute phase of the study

10. Have a visual or physical motor impairment that could interfere with participant's ability to perform study assessments, as assessed by the investigator

11. Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥2 x upper limit of normal (ULN) or a bilirubin level 1.5 x ULN unless due to a documented history of Gilbert's syndrome

12. Have estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73m2 as calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD EPI] 2009 creatinine equation at Visit 1 (Screening)

13. Have positive hepatitis C virus (HCV) antibody (Ab), hepatitis B surface antigen (HBs Ag), hepatitis A virus (HAV) IgM antibody (HAV-Ab [IgM]) or human immunodeficiency virus (HIV) test at Visit 1 (Screening)

14. Have a thyroid-stimulating hormone (TSH) level of <0.9 x lower limit of normal (LLN) or >1.2 x ULN on or off stable treatment for hyperthyroidism or hypothyroidism; if TSH is abnormal, evaluate reflex Free T3 and Free T4. If reflex testing is normal, the assessment of normal thyroid function will be determined based on the judgement of the investigator, following discussion with the medical monitor.

15. Have any other clinically significant abnormalities (significant would include laboratory deviations requiring acute medical intervention or further medical evaluation) in laboratory results at screening, including clinical chemistries, hematology, and urinalysis, and any clinical information that, in the judgment of the investigator or Sponsor, should preclude a participant's participation at study entry

16. Have exclusionary ECG abnormalities obtained at Visit 1 (Screening) or Visit 2 (Baseline) that are QT interval corrected using Fridericia's formula (QTcF) >450 msec in males or >470 msec in females, complete bundle branch block, evidence of myocardial infarction or ischemia, and predominantly nonsinus conducted rhythms. Other abnormalities can be exclusionary at the discretion of the principal investigator or medical monitor. See Section 6.3.5 of protocol for guidance on ECG interpretations.

17. Have a positive urine drug screen for amphetamines, barbiturates, cocaine, methadone, opioids, propoxyphene, tetrahydrocannabinol (THC), phencyclidine, or a positive blood alcohol level assessed by breathalyzer at Visit 1 (Screening) and Visit 2 (Baseline). For occasional (1 to 2 times per month maximum) cannabis users only, 1 retest is allowed and participant must agree to abstain from use for the duration of the study; a positive second test is exclusionary.

18. Have any use, by history, of Salvinorin A

19. Use of the following concomitant medications (contact the Sponsor-designated medical monitor to determine eligibility when in doubt):

1. Psychoactive medication including stimulants, benzodiazepines and anxiolytics, oral antipsychotics, mood stabilizers/anticonvulsants (carbamazepine, lamotrigine, etc.), lithium, antidepressants, S adenosylmethionine, melatonin, agomelatine, and hypnotics/sedatives within 5 half-lives or 14 days (whichever is longer) of Visit 2 (Baseline)

2. Fluoxetine and irreversible monoamine oxidase inhibitors within 4 weeks of Visit 2 (Baseline) depot antipsychotics within 2 months of Visit 2 (Baseline)

3. Opioid agonists and antagonists

20. Are currently taking or have taken within 5 half-lives of Visit 2 (Baseline) any medications or supplements.

21. Are women who are either pregnant or breastfeeding

22. Have participated (received study treatment) in a clinical study or any other type of medical research judged by the investigator or Sponsor to be scientifically or medically incompatible with this study within 30 days prior to Visit 1 (Screening). Contact the Sponsor-designated medical monitor to determine eligibility when in doubt.

23. Have participated in multiple interventional clinical studies, such that, in the opinion of the investigator or Sponsor the participant is not a suitable candidate for participation

24. Have previously completed or withdrawn from this study or any other study investigating BTRX 335140

25. Are investigator site personnel directly affiliated with this study, and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

26. Are employees of the Sponsor or are employees of any third-party organizations (TPOs) (eg, laboratory staff, study vendors and transportation providers) involved in the study who require exclusion of their employees

27. Has any of the following:

1. useful vision in only 1 eye from a pre-existing ophthalmic disease or amblyopia;

2. a corneal transplant in either eye;

3. corneal dystrophy or family history of corneal dystrophy;

4. severe dry eye syndrome (keratitis sicca);

5. will not or cannot cooperate with ophthalmic examination requiring pupillary dilation (includes history of severe adverse reaction to mydriatic agents or untreated narrow angle glaucoma). Note: The following ocular disorders are allowed: cataracts, prior cataract surgery, glaucoma (narrow angle glaucoma is allowed if definitively treated with laser peripheral iridectomy), macular degeneration, or ocular changes associated with diabetes mellitus or multiple sclerosis.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Neumora Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Neumora Investigator Site

Phoenix, Arizona, United States

Neumora Investigator Site

Bentonville, Arkansas, United States

Neumora Investigator Site

Little Rock, Arkansas, United States

Neumora Investigator Site

Bellflower, California, United States

Neumora Investigator Site

Culver City, California, United States

Neumora Investigator Site

Garden Grove, California, United States

Neumora Investigator Site

Glendale, California, United States

Neumora Investigator Site

Long Beach, California, United States

Neumora Investigator Site

Oakland, California, United States

Neumora Investigator Site

Riverside, California, United States

Neumora Investigator Site

San Jose, California, United States

Neumora Investigator Site

Santa Ana, California, United States

Neumora Investigator Site

Sherman Oaks, California, United States

Neumora Investigator Site

Torrance, California, United States

Neumora Investigator Site

Upland, California, United States

Neumora Investigator Site

Fernandina Beach, Florida, United States

Neumora Investigator Site

Jacksonville, Florida, United States

Neumora Investigator Site

Lauderhill, Florida, United States

Neumora Investigator Site

Miami Lakes, Florida, United States

Neumora Investigator Site

Orlando, Florida, United States

Neumora Investigator Site

Orlando, Florida, United States

Neumora Investigator Site

Sarasota, Florida, United States

Neumora Investigator Site

Atlanta, Georgia, United States

Neumora Investigator Site

Atlanta, Georgia, United States

Neumora Investigator Site

Atlanta, Georgia, United States

Neumora Investigator Site

Decatur, Georgia, United States

Neumora Investigator Site

Las Vegas, Nevada, United States

Neumora Investigator Site

Berlin, New Jersey, United States

Neumora Investigator Site

Brooklyn, New York, United States

Neumora Investigator Site

Jamaica, New York, United States

Neumora Investigator Site

New York, New York, United States

Neumora Investigator Site

Rochester, New York, United States

Neumora Investigator Site

Staten Island, New York, United States

Neumora Investigator Site

Dayton, Ohio, United States

Neumora Investigator Site

Oklahoma City, Oklahoma, United States

Neumora Investigator Site

Memphis, Tennessee, United States

Neumora Investigator Site

Wichita Falls, Texas, United States

Neumora Investigator Site

Clinton, Utah, United States

Countries

United States

References

Mathew SJ, Cutler AJ, Visitacion NC, Gold M, Yuan J, Aurora B. Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial. J Clin Psychopharmacol. 2025 May-Jun 01;45(3):267-276. doi: 10.1097/JCP.0000000000001967. Epub 2025 Apr 9.

Reference Type: DERIVED

PMID: 40199329 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://journals.lww.com/psychopharmacology/fulltext/9900/navacaprant,_a_novel_and_highly_selective_kappa.378.aspx

Mathew SJ, Cutler AJ, Visitacion NC, Gold M, Yuan J, Aurora B. Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults with Major Depressive Disorder: A Randomized, Double-blind Phase 2 Clinical Trial. Journal of Clinical Ps

Other Identifiers

NMRA-140

Identifier Type: OTHER

Identifier Source: secondary_id

K2-MDD-201

Identifier Type: -

Identifier Source: org_study_id